HLA Tissue Typing Class I & Class II (Donor) at Chughtai Lab

HLA Tissue Typing Class I & Class II (Donor) at Chughtai Lab

Human Leukocyte Antigen (HLA) Tissue Typing Class I and Class II for donors is a highly specialized molecular diagnostic test performed at Chughtai Lab in Pakistan. This sophisticated laboratory investigation is the cornerstone of transplant medicine, designed to evaluate the genetic compatibility between a potential organ or stem cell donor and a recipient. The Human Leukocyte Antigen system is a complex gene family located on chromosome 6, which encodes cell-surface proteins responsible for regulation of the immune system. These proteins help the body distinguish self from non-self. In the context of clinical transplantation, matching these antigens between the donor and recipient is paramount to minimizing the risk of graft rejection, graft-versus-host disease (GVHD), and other severe immunological complications.

The HLA Tissue Typing Class I and Class II (Donor) test at Chughtai Lab utilizes advanced molecular biology techniques, such as Polymerase Chain Reaction (PCR) and Sequence-Specific Oligonucleotide (SSO) hybridization, or Next-Generation Sequencing (NGS). Class I typing evaluates the HLA-A, HLA-B, and HLA-C loci, which are expressed on almost all nucleated cells in the body. Class II typing evaluates the HLA-DR, HLA-DQ, and HLA-DP loci, which are primarily expressed on antigen-presenting cells of the immune system. By identifying the specific alleles present at these loci in the donor, transplant teams can compare them with the recipient’s HLA profile to calculate the degree of histocompatibility. This precise genetic matching is essential for successful renal, hepatic, cardiac, and hematopoietic stem cell transplantations, ensuring optimal long-term graft survival and patient health.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis for HLA Tissue Typing. Donors should observe the following guidelines:

• No Fasting Required: There is no requirement to fast before this test. Donors may eat and drink normally prior to sample collection.
• Medication Disclosure: Inform the healthcare provider and lab staff of all current medications, especially immunosuppressants, chemotherapy agents, or recent experimental therapies.
• History of Blood Transfusions: It is critical to disclose any history of recent blood transfusions, as circulating donor white blood cells from a transfusion can occasionally interfere with molecular typing assays.
• Recent Bone Marrow Transplants: If the donor has previously received a bone marrow or stem cell transplant, this must be communicated, as it alters the genetic profile of the circulating blood cells.
• Hydration: Staying well-hydrated is recommended to facilitate easier venous access during blood collection.

During the Procedure

The sample collection process for HLA Tissue Typing Class I & Class II (Donor) at Chughtai Lab is straightforward, safe, and conducted under strict aseptic conditions:

• Patient Identification: The phlebotomist will verify the donor’s identity using at least two unique identifiers (e.g., full name, date of birth, or national identity card number) to ensure absolute accuracy in labeling.
• Venipuncture Site Selection: The donor will be seated comfortably, and a suitable vein, typically in the antecubital fossa of the arm, will be selected.
• Aseptic Preparation: The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) to prevent contamination of the sample.
• Sample Collection: A sterile, single-use needle is inserted into the vein, and approximately 3 to 5 mL of whole blood is drawn into an EDTA (purple-top) tube. EDTA is the preferred anticoagulant as it preserves cellular DNA for molecular testing.
• Post-Collection Care: The needle is gently removed, and a sterile cotton ball or adhesive bandage is applied to the puncture site with mild pressure to stop any bleeding.
• Duration and Experience: The entire venipuncture procedure takes less than five minutes. The donor may feel a brief, mild pinch as the needle enters the skin, but the process is generally painless.

When is a HLA Tissue Typing Class I & Class II (Donor) Performed?

Renal Transplantation Compatibility

Physicians request HLA Tissue Typing Class I & Class II for potential living or deceased kidney donors to assess immunological compatibility with the recipient. A high degree of HLA matching, particularly at the HLA-A, HLA-B, and HLA-DR loci, is strongly associated with reduced incidence of acute rejection episodes and improved long-term survival of the renal allograft. This test helps transplant surgeons determine if the donor-recipient pair is a viable match.

Hematopoietic Stem Cell and Bone Marrow Transplantation

In allogeneic hematopoietic stem cell transplantation (HSCT), HLA matching is critical. Physicians perform high-resolution HLA Class I and Class II typing on potential family or unrelated donors. A close match, ideally a 10/10 or 8/8 allele match (evaluating HLA-A, -B, -C, -DRB1, and -DQB1), is essential to prevent life-threatening Graft-versus-Host Disease (GVHD), where the donor’s immune cells attack the recipient’s organs, and to ensure successful donor cell engraftment.

Living Liver Donor Evaluation

While the liver is immunologically more tolerant than the kidneys or heart, HLA Tissue Typing is still performed for living liver donors. It provides a baseline genetic profile that helps predict the risk of post-transplant rejection and guides the post-operative immunosuppressive regimen. It is also valuable in cases where the recipient has pre-existing anti-HLA antibodies.

Preventing Graft-Versus-Host Disease (GVHD)

In cellular therapies and bone marrow transplants, matching Class II HLA antigens (specifically HLA-DRB1 and HLA-DQB1) is highly critical. If these loci are mismatched, the donor’s T-lymphocytes are highly likely to recognize the recipient’s tissues as foreign, initiating an aggressive immune response. Performing comprehensive Class II typing on the donor allows clinicians to select the donor with the lowest risk profile for GVHD.

Pre-existing Donor-Specific Antibody (DSA) Risk Assessment

When a recipient has been sensitized to foreign HLAs through previous transplants, pregnancies, or blood transfusions, they develop anti-HLA antibodies. By performing detailed Class I and Class II typing on the potential donor, clinicians can cross-reference the donor’s HLA antigens with the recipient’s antibody profile. This identifies if the recipient has Donor-Specific Antibodies (DSAs), which would cause immediate hyperacute rejection of the transplant.

What Does a HLA Tissue Typing Class I & Class II (Donor) Detect?

The HLA Tissue Typing Class I & Class II (Donor) test at Chughtai Lab detects and analyzes a wide array of genetic markers and parameters, including:

• HLA-A Locus Alleles: Identifies the specific Class I alleles inherited at the HLA-A locus.
• HLA-B Locus Alleles: Detects the specific Class I alleles present at the HLA-B locus.
• HLA-C Locus Alleles: Determines the Class I alleles at the HLA-C locus, crucial for NK cell interactions.
• HLA-DRB1 Locus Alleles: Identifies the primary Class II alleles at the HLA-DRB1 locus, highly critical for stem cell matching.
• HLA-DQB1 Locus Alleles: Detects the Class II alleles at the HLA-DQB1 locus.
• HLA-DPB1 Locus Alleles: Evaluates the Class II alleles at the HLA-DPB1 locus for high-resolution matching.
• Low-Resolution Antigen Groupings: Identifies the broad antigen families (2-digit resolution) suitable for solid organ transplants.
• High-Resolution Allele Typing: Identifies specific protein sequences (4-digit resolution or higher) required for bone marrow transplantation.
• Haplotype Sharing: Determines the set of HLA genes inherited together from a single parent, helping map family donor genetics.
• Homozygosity vs. Heterozygosity: Detects whether the donor carries identical or different alleles at each HLA locus.
• Presence of Rare HLA Alleles: Identifies uncommon genetic variants within the HLA complex that may affect matching.
• Null Alleles: Detects alleles that do not express cell-surface proteins, preventing false-positive match assumptions.
• DNA Concentration: Measures the quantity of genomic DNA extracted from the donor’s blood sample to ensure test validity.
• DNA Purity (A260/A280 ratio): Assesses the quality of the extracted DNA to prevent amplification failures during PCR.
• Amplification Controls: Verifies the success of internal PCR controls to ensure the reliability of the molecular assay.
• Sequence-Specific Primer (SSP) Binding: Detects specific primer amplification patterns indicating target allele presence.
• Sequence-Specific Oligonucleotide (SSO) Hybridization: Analyzes probe hybridization signals to define the HLA profile.
• Next-Generation Sequencing (NGS) Reads: Provides clonal sequencing data for absolute allele resolution when high-resolution typing is ordered.
• Cross-Reactive Groups (CREGs): Identifies shared public epitopes among different HLA antigens to assist in finding acceptable mismatches.
• MHC Class I Chain-Related Gene A (MICA): Optionally detects non-classical HLA markers that may influence transplant outcomes.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, molecular diagnostics and histocompatibility testing are performed with the utmost precision and efficiency. Because HLA Tissue Typing involves complex DNA extraction, amplification, and detailed sequencing or hybridization analysis, the turnaround time typically ranges from 5 to 7 working days. Chughtai Lab offers seamless digital access to diagnostic reports. Patients and donors can easily view, download, and print their reports via the official Chughtai Lab website or the Chughtai Lab mobile application. Additionally, automated SMS notifications are sent to the registered mobile number as soon as the report is finalized and verified by a consultant pathologist.

HLA Tissue Typing Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HLA-A Locus	Two functional alleles identified (e.g., HLA-A*02, HLA-A*24)	Presence of null alleles or rare mutations affecting expression
HLA-B Locus	Two functional alleles identified (e.g., HLA-B*08, HLA-B*35)	Atypical allele variants associated with disease susceptibility
HLA-C Locus	Two functional alleles identified (e.g., HLA-C*07, HLA-C*04)	Mismatches that may trigger natural killer (NK) cell activation
HLA-DRB1 Locus	Two functional alleles identified (e.g., HLA-DRB1*03, DRB1*15)	Allelic mismatches highly prone to initiating T-cell rejection
HLA-DQB1 Locus	Two functional alleles identified (e.g., HLA-DQB1*02, DQB1*06)	Mismatches linked to accelerated antibody-mediated rejection
DNA Sample Quality	High purity (A260/A280 ratio of 1.7–2.0) and adequate concentration	Degraded DNA or low concentration requiring sample recollection
Match Grade (Donor-Recipient)	High compatibility (e.g., 10/10 or 8/8 allele match)	Low compatibility or major mismatches (e.g., 4/10 or 5/8 match)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HLA Tissue Typing Class I & Class II (Donor)?

• Experienced Healthcare Professionals: Chughtai Lab features a dedicated team of consultant pathologists, molecular biologists, and geneticists specializing in histocompatibility.
• Patient-Focused Care: The lab prioritizes donor comfort and clarity throughout the sample collection and reporting process.
• Quality Diagnostic Services: Utilizing standardized molecular assays ensures highly reproducible and clinically dependable HLA typing results.
• Professional Reporting: Reports are structured clearly, providing detailed allele designations essential for transplant coordinators and surgeons.
• Modern Diagnostic Approach: Chughtai Lab employs state-of-the-art PCR, SSO, and sequencing technologies for precise genetic analysis.
• Comfortable Environment: All collection centers across Pakistan maintain clean, hygienic, and welcoming spaces for donors.
• Convenient Location: With an extensive network of collection centers in Lahore, Karachi, Islamabad, and other major cities, accessing services is highly convenient.
• Commitment to Accurate Diagnosis: Strict internal and external quality control protocols are maintained to ensure the highest diagnostic accuracy.